October 2nd, 2026FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p DeletionThis moves the noncovalent BTK inhibitor into the first-line setting for certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.Read more
October 2nd, 2026Pipeline Advances in Sjögren Disease Bring Targeted Therapies CloserPhase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.Read more
October 1st, 2026Experts Highlight PMOS Diagnostic, Care Gaps Amid Recent Name ChangeAlthough PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.Read more
October 1st, 2026Lung Cancer Screening Lags for People With HIV as Eligibility TriplesAmong people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.Read more
October 1st, 2026Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2DSurvodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.Read more
September 30th, 2026Sarcoma-to-Heart Case Highlights Need for Multidisciplinary CareA rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.Read more
September 30th, 2026Weekend Catch-Up Sleep Linked to Lower Odds of Overactive BladderWeekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.Read more
September 30th, 2026Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2DThe triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.Read more